Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial

• Ngā kaituhi matua: Jasmini Alagaratnam (Author), Wolfgang Stöhr (Author), Elizabeth Hamlyn (Author), Kholoud Porter (Author), Jamie Toombs (Author), Amanda Heslegrave (Author), Henrik Zetterberg (Author), Magnus Gisslén (Author), Jonathan Underwood (Author), Mauro Schechter (Author), Pontiano Kaleebu (Author), Giuseppe Tambussi (Author), Sabine Kinloch (Author), Jose M. Miro (Author), Anthony D. Kelleher (Author), Abdel Babiker (Author), John Frater (Author), Alan Winston (Author), Sarah Fidler (Author)
• Hōputu: Pukapuka
• I whakaputaina: Elsevier, 2024-06-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Objective: Antiretroviral therapy (ART)-conferred suppression of HIV replication limits neuronal injury and inflammation. ART interruption tests efficacy in HIV cure trials and viral rebound after ART interruption may induce neuronal injury. We investigated the impact of protocol-defined ART interru...